Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial

BACKGROUND AND OBJECTIVE: Nonacog beta pegol (N9‐GP) and recombinant factor IX‐Fc fusion protein (rFIXFc) are extended half‐life rFIX compounds. We report the first single‐dose pharmacokinetic trial of N9‐GP and rFIXFc. PATIENTS/METHODS: Paradigm 7 was a multicenter, open‐label, randomized, crossove...

Descripción completa

Detalles Bibliográficos
Autores principales: Escuriola Ettingshausen, Carmen, Hegemann, Inga, Simpson, Mindy L., Cuker, Adam, Kulkarni, Roshni, Pruthi, Rajiv K., Garly, May‐Lill, Meldgaard, Rikke M., Persson, Paula, Klamroth, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles: Haemostasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462750/
https://www.ncbi.nlm.nih.gov/pubmed/31011711
http://dx.doi.org/10.1002/rth2.12192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462750/
https://www.ncbi.nlm.nih.gov/pubmed/31011711
http://dx.doi.org/10.1002/rth2.12192

Ejemplares similares